Gritstone bio Added to the Nasdaq Biotechnology Index
Gritstone bio Added to the Nasdaq Biotechnology Index
EMERYVILLE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.
亞洲網加利福尼亞州埃默裏維爾12月13日電格里斯通生物公司(納斯達克代碼：GRTS)是一家臨牀階段的生物技術公司，開發下一代癌症和傳染病免疫療法。該公司今天宣佈，該公司已被納入納斯達克生物技術指數(納斯達克代碼：NBI)，於2021年12月20日(星期一)開市前生效。
The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the NASDAQ Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.
納斯達克生物技術指數旨在跟蹤在納斯達克股票市場上市的一系列證券的表現®(納斯達克®)，根據行業分類基準(ICB)被歸類為生物技術或製藥類。納斯達克生物技術指數是根據改進的市值加權方法計算的。納斯達克生物技術指數成份股公司必須符合資格要求，包括最低市值、日均交易量和上市公司的調味性等標準。納斯達克每年12月挑選一次選民。
For more information about the NASDAQ Biotechnology Index, please visit .
欲瞭解更多納斯達克生物科技指數詳情，請瀏覽。
About Gritstone
Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company, is developing the next generation of immunotherapies against multiple cancer types and infectious diseases. Gritstone develops its products by leveraging two key pillars—first, a proprietary machine learning-based platform, Gritstone EDGE™, which is designed to predict antigens that are presented on the surface of cells, such as tumor or virally-infected cells, that can be seen by the immune system; and, second, the ability to develop and manufacture potent immunotherapies utilizing these antigens to potentially drive the patient's immune system to specifically attack and destroy disease-causing cells. The company's lead oncology programs include an individualized neoantigen-based immunotherapy, GRANITE, and an "off-the-shelf" shared neoantigen-based immunotherapy, SLATE, which are being evaluated in clinical studies. Within its infectious disease pipeline, Gritstone is advancing CORAL, a COVID-19 program to develop a second-generation vaccine, with support from departments within the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI) and through a license agreement with La Jolla Institute for Immunology (LJI). Additionally, the company has a global collaboration for the development of a therapeutic HIV vaccine with Gilead Sciences. For more information, please visit gritstone.com.
關於格里斯通
砂石生物公司(納斯達克代碼：GRTS)是一家臨牀階段的生物技術公司，正在開發針對多種癌症類型和傳染病的下一代免疫療法。Gritstone通過利用兩個關鍵支柱來開發其產品-第一，基於機器學習的專有平臺Gritstone EDGE™，旨在預測免疫系統可以看到的細胞表面的抗原，如腫瘤或病毒感染的細胞；第二，開發和製造有效的免疫療法的能力，利用這些抗原潛在地驅動患者的免疫系統專門攻擊和摧毀致病細胞。該公司的領先腫瘤學項目包括一種個性化的基於新抗原的免疫療法Granite，以及一種“現成的”共享的基於新抗原的免疫療法Slate，這兩種療法正在臨牀研究中進行評估。在其傳染病研發項目中，格里斯通正在推進“新冠肺炎”項目--開發第二代疫苗的珊瑚項目，該項目得到了美國國立衞生研究院、比爾和梅林達·蓋茨基金會、防疫創新聯盟的支持，並與拉霍亞免疫學研究所簽訂了許可協議。此外，該公司還與吉利德科學公司在開發治療性艾滋病疫苗方面進行了全球合作。欲瞭解更多信息，請訪問gritstone.com。
Gritstone Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone's therapeutic programs; the advancements in the company's ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone's research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone's ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone's most recent Quarterly Report on Form 10-Q filed on November 3, 2021 and any current and periodic reports filed with the Securities and Exchange Commission.
砂石前瞻陳述
本新聞稿包含前瞻性陳述，包括但不限於與格里斯通治療計劃的潛力有關的陳述；該公司正在進行的臨牀試驗的進展；與正在進行的臨牀試驗和未來臨牀試驗的啟動有關的數據宣佈的時間安排。此類前瞻性陳述涉及大量風險和不確定因素，可能導致格里斯通公司的研究和臨牀開發計劃、未來結果、業績或成就與前瞻性陳述中明示或暗示的內容大不相同。這些風險和不確定因素包括藥物開發過程中固有的不確定因素，包括格里斯通項目的早期開發階段、設計和進行臨牀前和臨牀試驗的過程、監管審批過程、監管申報的時間、與生產藥品相關的挑戰、格里斯通成功建立、保護和捍衞其知識產權的能力，以及其他可能影響現有現金為運營提供資金的充足性的問題。Gritstone公司不承擔更新或修改任何前瞻性陳述的義務。欲進一步瞭解可能導致實際結果與這些前瞻性陳述中表述的結果不同的風險和不確定因素，以及與公司總體業務相關的風險，請參閲格里斯通公司於2021年11月3日提交的最新的10-Q表格季度報告以及提交給證券交易委員會的任何當前報告和定期報告。
Gritstone Contacts
Media:
Dan Budwick
1AB
(973) 271-6085
dan@1abmedia.com
砂石觸點
媒體：
丹·佈德威克
1AB
(973) 271-6085
電子郵箱：Dan@1abmedia.com
Investors:
Tim McCarthy
LifeSci Advisors
tim@lifesciadvisors.com
投資者：
蒂姆·麥卡錫
生活科學顧問(LifeSci Advisors)
郵箱：Tim@lifescivisors.com
譯文內容由第三人軟體翻譯。